RPEP-14730 · 2026Bile acid sequestrants (BAS) reduced bile acid levels in vitro and disrupted bile acid-phospholipid mixed micelles (BAPMM), increasing the concentration of free octreotide available to cross intestinal membranes. This enhanced peptide membrane flux without compromising the enzymatic stability that micelles provide. However, the in vivo results were disappointing — oral colestipol (a BAS) did not significantly improve octreotide absorption in animals.
Additionally, cyclic E-cadherin peptide (ECP) permeation enhancers were tested but their specific in vivo results were not detailed. The study highlights that BAPMM sequestration is an important but not sole barrier to oral peptide bioavailability.
Al-Tamimi, Zahraa; Feng, Mei; Elballa, Waleed; Houser, Sydney; Hageman, Michael J ·
RPEP-14731 · 2026From 22,100 research articles screened, the systematic review included observational studies comparing SGLT2 inhibitors and GLP-1 receptor agonists in real-world type 2 diabetes patients.
Key pooled analysis findings:
- Heart failure and MACE/revascularization risk ratios were slightly higher with SGLT2 inhibitors compared to GLP-1 agonists (meaning GLP-1 agonists had a slight edge for cardiovascular event reduction)
- Renal outcome odds ratios also slightly favored GLP-1 agonists
- However, SGLT2 inhibitors showed lower hypoglycemic events and lower all-cause mortality rates
- SGLT2 inhibitors were more effective specifically at reducing hospitalization for heart failure
The findings suggest these drug classes have complementary strengths rather than one being universally superior.
Alam, Aftab; Imran, Mohd; Ur Rehman, Zia; Sahoo, Biswa Mohan; Mahapatra, Manoj Kumar ·
RPEP-14733 · 2026Across 58 obese women with PCOS treated with semaglutide in routine clinical practice, mean weight loss was 12.6 ± 9.6 kg, representing 11.4% of total body weight (p < 0.0001). Seventy-nine percent of participants lost more than 5% of their body weight — the threshold considered clinically meaningful for PCOS.
Mean BMI dropped from 40.7 to 36.2 kg/m² (p < 0.0001). Systolic blood pressure fell by 6.3 mmHg (p = 0.012). HbA1c decreased from 35.3 to 33 mmol/mol (p = 0.0014). Total cholesterol dropped from 4.8 to 4.45 mmol/L (p = 0.03). Among those with irregular periods, 50% reported subjective improvement, while 33% with acne and 29% with hirsutism also noted improvements.
Alawami, Fatimah; Novaes, Olivia; Gibney, James; Phelan, Niamh; Behan, Lucy Ann; Owens, Lisa · Retrospective Cohort
RPEP-14734 · 2026In diabetic Wistar rats treated for eight weeks, tirzepatide produced comprehensive reproductive improvements: restored testosterone and gonadotropin levels, enhanced sperm quality, reduced lipid peroxidation (oxidative fat damage), and preserved testicular architecture with increased PCNA expression (cell proliferation) and reduced caspase-3-mediated apoptosis (programmed cell death).
The protective mechanism involved activation of the Nrf2/Keap1 antioxidant pathway and normalization of steroidogenic gene expression. Crucially, a pair-fed diabetic control group demonstrated that these effects were largely independent of weight reduction — pointing to direct tissue-protective actions of tirzepatide. All reproductive outcomes were superior to those achieved with metformin.
Albokhadaim, Ibrahim ·
RPEP-14736 · 2026Expert consensus supports multidisciplinary CKM syndrome management with expanded GLP-1 RA access, particularly semaglutide, to address Kuwait's high burden of obesity and metabolic disease.
Aldahi, Waleed A; Alenezi, Abdullah; Alessa, Thamer; Alhamdan, Rashed; Al-Humood, Khaldoon A; Alqallaf, Ahmed; Alotaibi, Torki; Alrajab, Heba; Alshammari, Abdulmuhsen M; Alyousef, Anas M; Alsayed Hashem, Asrar; Rizzo, Manfredi ·
RPEP-14737 · 2026GLP-1 receptor agonists showed consistent weight loss efficacy across patient subgroups defined by age, sex, race/ethnicity, baseline BMI, and baseline HbA1c.
Alexander, G Caleb; Xiao, Xuya; Dilek, Sophie; Lewis, Sydney; Deng, Qilin; Kim, Minji; Bolanle, Dami; Saldanha, Ian J; Mehta, Hemalkumar B ·
RPEP-14738 · 2026Patients experienced weight regain after discontinuing GLP-1 medications, with patterns influenced by the duration of prior treatment.
Alexander, G Caleb; Xu, Yizhen; Xiao, Xuya; Lewis, Sydney V; Zeger, Scott; Mehta, Hemalkumar B ·
RPEP-14739 · 2026Joint expert guidance from three major U.S. obesity organizations provides updated, evidence-graded recommendations for pharmacological obesity management.
Alexander, Lydia; Purnell, Jonathan Q; Burridge, Karlijn; Cornier, Marc-André; Golden, Angela; Bade, Deborah; Look, Michelle; Nadglowski, Joe; Ávila-Oliver, Camila; Novillo, Francisco; Rojas-Gómez, Ana María; Hussey, Brad; Salas, Ximena Ramos ·
RPEP-14740 · 2026GLP-1 receptor agonist use was not associated with increased hypothyroidism incidence compared to DPP-4 inhibitor use in Saudi Arabian adults.
Alfakhri, Almaha; Almadani, Ohoud; Alroba, Raseel; Alrwisan, Adel; Alshaya, Omar; Albogami, Yasser ·
RPEP-14741 · 2026In vitro metabolic profiling identified breakdown products of pramlintide, cagrilintide, and KBP-042, supporting development of anti-doping detection methods for next-generation weight loss peptides.
Alhalabi, Hana; Borschel, Lisa; Le Foll, Christelle; Thomas, Andreas; Bally, Lia; Thevis, Mario ·
RPEP-14742 · 2026GLP-1 RA use for weight management was prevalent among overweight/obese adults in Eastern Saudi Arabia, with specific demographic and health factors predicting use.
Alhussain, Khalid; Alshakhs, Zainab; Albaqshi, Layla; Alshaqaqiq, Fawatim; Alrabiah, Mohammed; Tripathi, Rina ·
RPEP-14743 · 2026Study protocol describes a peer-led BNP screening plus telecardiology intervention designed to detect methamphetamine-associated heart failure in rural communities.
Alias-Ferri, Maria; Kersey, Cooper B; Shalen, Evan F; Cook, Ryan; Gregoire, Devin; Hoffman, Kim; Beam, Michelle; Levander, Ximena A; Pertl, Kellie; Stensby, Alexis; Gonzales, Paul; Smith, Shanna; Evernden, Tabetha; Longenecker, Chris T; Korthuis, P Todd; Chan, Brian ·
RPEP-14744 · 2026GLP-1 RAs and emerging metabolic hormone therapies show significant potential for slowing CKD progression, particularly within the CKM syndrome framework.
Alicic, Radica Z; Neumiller, Joshua J; Tuttle, Katherine R ·
RPEP-14745 · 2026Semaglutide 2.4mg produced significant weight and fat loss but also reduced lean body mass, while handgrip strength was generally preserved through 12 months.
Alissou, Mathieu; Demangeat, Thomas; Folope, Vanessa; Van Elslande, Hélène; Lelandais, Hélène; Blanchemaison, Julia; Cailleaux, Pierre-Emmanuel; Guney, Suzan; Aupetit, Alexandra; Aubourg, Agnès; Rapp, Clément; Petit, André; Godin, Morgane; Vignal, Luc; Grigioni, Sébastien; Déchelotte, Pierre; Colange, Guillaume; Coëffier, Moïse; Achamrah, Najate ·
RPEP-14746 · 2026Limited retrospective evidence suggests GLP-1 RAs may be safe regarding mortality, MACE, and MAKE in kidney transplant recipients with type 2 diabetes.
Aliyeva, Turkan; Natche, Julia; Jiakponna, Enyinnaya Calistus; Ahmad, Feras; Eze, Belinda; Nawaz, Usama Hassan; El-Amri, Imane; Shrestha, Sheelu ·
RPEP-14747 · 2026UP5-C-Levo demonstrated enhanced antimicrobial activity against resistant bacteria compared to its individual components, with improved safety.
Almaaytah, Ammar; Rashdan, Aseel; Mhaidat, Nizar; Sabi, Salsabeel H ·
RPEP-14748 · 2026Tirzepatide treatment across the SURMOUNT-1-4 trials was not associated with worsening nutritional status despite appetite and dietary intake reduction.
Almandoz, Jaime P; Pickett-Blakely, Octavia; Tewksbury, Colleen; Stefanski, Adam; Gonsahn-Bollie, Sylvia; Dimitriadis, Georgios K; Murro, Ada Leticia; Cao, Dachuang; Meng, Qier; Neff, Lisa M ·
RPEP-14749 · 2026MDP-1 peptide enables direct detection of HPV nucleic acids from liquid cytology samples without requiring nucleic acid extraction.
Almas, Sadia; Karki, Salima; Carpenter, Rob E; Tamrakar, Vaibhav K; Sharma, Aditya; Suri, Kamalpreet; Sharma, Rahul ·
RPEP-14750 · 2026GIP is emerging as a critical therapeutic target alongside GLP-1, with dual agonists showing enhanced efficacy for type 2 diabetes management.
Almorza-Gomar, David; Díaz-Gómez, Alfredo; Visiedo, Francisco; García-Ortiz, José-Carlos; Camacho-Ramírez, Alonso; Ribelles-García, Antonio; Prada-Oliveira, José-Arturo; Pérez-Arana, Gonzalo-Martín ·
RPEP-14751 · 2026Emerging evidence suggests GLP-1 RAs may improve HS outcomes in obese patients through combined weight reduction and anti-inflammatory mechanisms.
Almukhadeb, Eman; Nagshabandi, Khalid Nabil; Alshehri, Naif; Alosaimi, Khalid; Almusa, Hala Abdullah; Almudimeegh, Almuntsrbellah ·
RPEP-14752 · 2026Tirzepatide did not protect against cisplatin-induced neurotoxicity or cognitive impairment in female rats.
Almutairi, Hanan Mubarak; Alhowail, Ahmad Hamad ·
RPEP-14753 · 2026A dual-channel fluorescence assay can distinguish between cell-penetrating and pore-forming peptide mechanisms by mapping different patterns of membrane permeabilization.
Alnajjar, Mohammad A; Schöpper, Sandra N; Pramod, Malavika; Reingolz, Thomas; Müller, Lina; Neumann, Justin; Nilam, Mohamed; Nau, Werner M; Hennig, Andreas ·
RPEP-14754 · 2026Orforglipron demonstrated significant improvements in weight, HbA1c, blood pressure, and lipid parameters across pooled phase 2 and 3 trial data.
Alper, Adir; Peleg, Gal; Fagin, Adina; Shah, Priyansh; Chowdhury, Ishmum; Gonzales, Antony; Faillace, Robert ·
RPEP-14755 · 2026Both SGLT2 inhibitors and GLP-1 RAs significantly reduce cardiovascular and renal events in type 2 diabetes, with potential differential benefits for specific outcomes.
Alqurain, Aymen A; Salem, Manal; Algarzai, Bashayer A; Eljadi, Eman M; Elsayed, Hazem S; Almuhanna, Ahmed; Albuhayji, Deema S; Salami, Mohammad; Alzahrani, Joud; Alsayyali, Juri; Alqarni, Abdulrahman; Alqahtani, Nessreen; Alotaibi, Fay T; Alyami, Gharam G ·
RPEP-14756 · 2026Two patients without typical risk factors developed pancreatic mucinous cystic neoplasms following GLP-1 RA use, suggesting a possible association requiring further investigation.
Alsaleh, Nourah Mohammed; Abo Alshamat, Renad; Almrzouqi, Wejdan; Alhebshi, Mohammed; Aljuhani, Turky; Almahdi, Rahf; Almaghrabi, Majed; Rammal, Almotasembillah; Ageel, Amro; Alzahrani, Mohammed Ahmad ·
RPEP-14757 · 2026The most influential incretin therapy publications cluster around GLP-1 RA efficacy, cardiovascular outcomes, and weight management — reflecting the field's rapid clinical expansion.
Alsaygh, Ehab F; Aljarboa, Abdullah M; Alhazmi, Adel A; Alhazmi, Abdullah S; Alraddadi, Osamah A; Althagafi, Aseel A; Alhojele, Mohmmed F ·
RPEP-14758 · 2026A 16-year-old developed acute DVT within 14 days of starting oral semaglutide 7mg, suggesting a possible temporal association with GLP-1 RA initiation.
Alsermani, Maamoun; Ali Alkahmous, Baraa; Alhutayrashi, Arwa A; Alshalhoob, Fai S; Abulrahman Almosaiteer, Sarah; Aljubayri, Eman; Saleh Alwabel, Assia; Sermani, Anas ·
RPEP-14759 · 2026Saudi consensus panel recommends integrated CRMD management with semaglutide as a cornerstone therapy, citing robust evidence across glycemic, weight, cardiovascular, renal, and hepatic outcomes.
Alshaikh, Abdulrahman; Alshehri, Ali; Alzubaidi, Lamya; Elbadawi, Hussein; Alsaeed, Abdulghani; Almehthel, Mohammed; Aldahash, Raed; Alsabaan, Fahad; Alotaibi, Metib; Alghamdi, Khalid; Alamri, Hussein; Bakhsh, Abdulmohsen; Evans, Marc; Issak, Emad R; Alsifri, Saud ·
RPEP-14760 · 2026Liraglutide combined with lifestyle modification was more effective than lifestyle modification alone for weight loss in Saudi adults with obesity and comorbidities.
AlTaib, Hanan N; AlAqeel, Reem; Arafat, Amr A; Kunnathodi, Faisal; AlShaikh, Abdulmajeed; AlOtaibi, Haifa F ·
RPEP-14761 · 2026A child with a novel ALMS1 nonsense variant and Alström syndrome showed favorable metabolic response to GLP-1 RA therapy.
Alvarez, Griselda; Huang, Alden; Grody, Wayne W; Yazdani, Shahram ·
RPEP-14762 · 2026NetMHCIIphosPan achieves superior prediction of HLA class II presentation of phosphorylated peptides compared to existing methods.
Alvarez, Heli M Garcia; Kaabinejadian, Saghar; Yari, Hooman; Shepherd, Chloe M; Hildebrand, William H; Sette, Alessandro; Peters, Bjoern; Parker, Robert; Ternette, Nicola; Nielsen, Morten ·
RPEP-14763 · 2026Systematic exclusion of CKD patients from heart failure trials creates major evidence gaps for co-management of these frequently coexisting conditions.
Alvi, Amaan; Singamala, Hithyshi; Gadde, Sai Surya Vamsi; Javvaji, Chaitanya Kumar ·
RPEP-14764 · 2026Tyrothricin inhibited T. gondii tachyzoite proliferation in vitro, with proteomics identifying potential molecular targets in the parasite.
Amdouni, Yosra; Boubaker, Ghalia; Müller, Joachim; Sousa, Maria Cristina Ferreira de; Hänggeli, Kai Pascal Alexander; Uldry, Anne-Christine; Braga-Lagache, Sophie; Heller, Manfred; Hemphill, Andrew ·
RPEP-14765 · 2026Gut microbiome removal altered antimicrobial peptide expression and pathogen susceptibility in H. armigera larvae.
Amiri Domari, Motahareh; Khani, Abbas; Sahebzadeh, Najmeh; Najimi, Mohsen; Mehrabadi, Mohammad ·
RPEP-14766 · 2026GLP-1 RA use was associated with lower incidence of anxiety, depression, self-harm, and suicidality compared to DPP-4i, sulfonylureas, and SGLT2i in propensity-matched cohorts.
Anagnostakis, Filippos; Kokkorakis, Michail; Anastasiou, Georgia; Nagarajan, Shrihari; Mantzoros, Christos S ·
RPEP-14767 · 2026GLP-1 receptor agonists and SGLT2 inhibitors showed equivalent dementia risk (HR 1.01, 95% CI 0.90–1.13) in propensity-matched diabetic adults.
Anagnostakis, Filippos; Kokkorakis, Michail; Nagarajan, Shrihari; Anastasiou, Georgia; Mantzoros, Christos S ·
RPEP-14768 · 2026Intravenous CGRP induced light-aversion and cephalic allodynia in male and female rats, providing a translational model for migraine photophobia.
Andersen, Veronika K; Hansen, Bjarke S; Fungbrant, Emelie; Hestehave, Sara; Haanes, Kristian A; Nordahl, Karin M L ·
RPEP-14769 · 2026SGLT2i and GLP-1 RA prescribing rates are substantially below guideline recommendations in Swedish primary care patients with IHD and T2D.
Andersson, Tobias; Bager, Johan-Emil; Hellgren, Margareta; Åberg, Maria; Mourtzinis, Georgios ·
RPEP-14770 · 2026Standard fasting guidelines plus withholding one semaglutide dose may not reliably ensure gastric emptying before endoscopy, with effects varying even in the same patient.
Ando, Kazuo; Takenoshita, Moe; Wei, Mike Tzuhen ·
RPEP-14771 · 2026Low-dose tirzepatide (2.5-5mg) produced significant weight loss and metabolic improvements in 12 weeks in adults with obesity without diabetes.
Angelopoulos, Nikolaos; Androulakis, Ioannis; Rizoulis, Andreas; Boniakos, Anastasios; Fousteris, Evangelos; Mentzelopoulou, Voula; Petkova, Valentina; Paparodis, Rodis; Zianni, Dimitra; Florakis, Dimos; Korakovouni, Areti; Mouslech, Zadalla; Livadas, Sarantis; Tzoulis, Ploutarchos ·
RPEP-14772 · 2026Combined intraduodenal lauric acid and L-tryptophan synergistically stimulated GLP-1/CCK release and reduced postprandial glucose in type 2 diabetes.
Anjom-Shoae, Javad; Fitzgerald, Penelope C E; Rose, Braden D; Bitarafan, Vida; Rehfeld, Jens F; Horowitz, Michael; Feinle-Bisset, Christine ·
RPEP-14773 · 2026Multiple strategies — structural modifications, conjugation, and formulation approaches — can significantly enhance arginine-rich CPP intracellular delivery efficiency.
Anjous, Rachel; Kavyashree, P; Saha, Abhishek ·
RPEP-14774 · 2026LL-37 drives rosacea pathogenesis by activating Jak1/STAT1 signaling in keratinocytes, inducing CXCL10-mediated T-cell recruitment to the skin.
Ansari, Abdul W; Habib, Tanwir; Ahmad, Fareed; Raheed, Thesni; Elizabeth, Cynthia S; Al-Harami, Sara; Jochebeth, Anh; Steinhoff, Martin ·
RPEP-14775 · 2026CGRP offers multiple cardioprotective mechanisms — vasodilation, anti-inflammation, anti-fibrosis, and neurohormonal counterregulation — that may be therapeutically exploitable in heart failure.
Ansari, Shazia; Aran, Khadga Raj ·
RPEP-14776 · 2026Lipid monolayer models reveal that AMP selectivity is driven by specific lipid signatures that differentiate bacterial, cancerous, and senescent cell membranes from healthy cells.
Antelo-Riveiro, Paula; Garcia-Fandino, Rebeca; Piñeiro, Ángel ·
RPEP-14777 · 2026GLP-1 RA and SGLT2i prescribing in Japan is rising rapidly, with prescribing patterns increasingly differentiated by patient characteristics like age, BMI, and kidney function.
Aoyama, Kazuki; Okada, Akira; Kaneko, Hidehiro; Azegami, Tatsuhiko; Suzuki, Yuta; Meguro, Shu; Fujiu, Katsuhito; Takeda, Norifumi; Morita, Hiroyuki; Node, Koichi; Yamauchi, Toshimasa; Nangaku, Masaomi; Takeda, Norihiko; Yasunaga, Hideo; Hayashi, Kaori ·
RPEP-14778 · 2026Cyclic peptide cyclo-(His-Phe) chelated copper and zinc nanoparticles demonstrated antimicrobial activity and selective anticancer effects against osteosarcoma cells.
Apostolidou, Chrysanthi Pinelopi; Charalambidis, Georgios; Gialouri, Aikaterini; Chatzinikolaidou, Maria; Mitraki, Anna ·
RPEP-14779 · 2026GLP-1 RAs provide robust cardiorenal protection in metabolic diseases, with mounting evidence supporting their use beyond glycemic control.
Apperloo, Ellen M; Heerspink, Hiddo J L; van Raalte, Daniël H; Muskiet, Marcel H A ·
RPEP-14780 · 2026The estrous cycle moderates GLP-1 RA effects on food intake and body weight, with brainstem GLP-1 receptor expression varying across cycle phases.
Applebey, Sarah V; Xiao, Allison G; Reiner, Benjamin C; Hayes, Matthew R ·
RPEP-14781 · 2026NP-3a transitions from ~23 intramolecular hydrogen bonds in compact form to ~122 water interactions in solution, then anchors to lipid membranes through specific hydrogen bonding patterns.
Aquino, Ana Clara D; Mendanha, Karinna; Georg, Herbert de C; Colherinhas, Guilherme ·